{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T10:53:20Z","timestamp":1794135200886,"version":"4.8.0"},"reference-count":20,"publisher":"SLACK, Inc.","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ophthalmic Surg Lasers Imaging Retina"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background and Objective<\/jats:title>\n                    <jats:p>This study will report safety and efficacy of pegcetacoplan for geographic atrophy (GA) secondary to age-related macular degeneration (AMD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>GALE is a phase 3, open-label, multicenter, 36-month extension of the OAKS and DERBY studies. Patients who received pegcetacoplan monthly (PM) or every other month (PEOM) in OAKS or DERBY continued the same regimen in GALE (PM-PM and PEOM-PEOM); sham-observed patients initiated pegcetacoplan, maintaining the same interval.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In the first 6 months of GALE, 3.0% of study eyes developed exudative AMD, 1.3% intraocular inflammation, 0.1% ischemic optic neuropathy, and none endophthalmitis. Pegcetacoplan reduced GA growth rate by 39% (PM-PM) and 32% (PEOM-PEOM), with increasing efficacy over time across GA subtypes. In eyes with nonsubfoveal GA, pegcetacoplan reduced GA growth rate by 45% (PM-PM) and 33% (PEOM-PEOM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Pegcetacoplan reduced GA growth rate up to 45% with increasing efficacy over 30 months and demonstrated a favorable safety profile.<\/jats:p>\n                    <jats:p>\n                      <jats:bold>\n                        [\n                        <jats:italic toggle=\"yes\">Ophthalmic Surg Lasers Imaging Retina<\/jats:italic>\n                        2025;56:398\u2013406.]\n                      <\/jats:bold>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3928\/23258160-20250217-01","type":"journal-article","created":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T08:29:32Z","timestamp":1747297772000},"page":"398-406","source":"Crossref","is-referenced-by-count":17,"title":["Pegcetacoplan for Geographic Atrophy Over 30 Months: Data From OAKS, DERBY, and the GALE Long-Term Extension Study"],"prefix":"10.3928","volume":"56","author":[{"given":"Roger A.","family":"Goldberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Boyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank G.","family":"Holz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathew W.","family":"MacCumber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunir J.","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora M.","family":"Lad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Steinle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Singh","family":"Rishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Pearce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Ach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramiro","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Tsuboi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J.","family":"Ferrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline R.","family":"Baumal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles C.","family":"Wykoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2308","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2017.08.038"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2017.11.036"},{"key":"e_1_3_2_4_2","volume-title":"Syfovre [package insert]","year":"2023","unstructured":"Syfovre [package insert]. Apellis Pharmaceuticals; 2023."},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2023.103757"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01520-9"},{"key":"e_1_3_2_7_2","unstructured":"Apellis Pharmaceuticals. FDA approves SYFOVRETM (pegcetacoplan injection) as the first and only treatment for geographic atrophy (GA) a leading cause of blindness. February 17 2023. Accessed March 18 2025. https:\/\/investors.apellis.com\/news-releases\/news-release-details\/fda-approves-syfovretm-pegcetacoplan-injection-first-and-only"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.07.011"},{"key":"e_1_3_2_9_2","unstructured":"Apellis Pharmaceuticals. Apellis reports analysis from phase 1b geographic atrophy study. April 28 2020. Accessed March 18 2025. https:\/\/investors.apellis.com\/news-releases\/news-release-details\/apellis-reports-analysis-phase-1b-geographic-atrophy-study"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2006.09.016"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1080\/09286580591005723"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2018.1544"},{"key":"e_1_3_2_13_2","volume-title":"Presented at EURETINA Congress","author":"Holz FG","unstructured":"Holz FG, Li C, Burch M, Ribeiro R, Steinle N. Efficacy and safety of pegcetacoplan in patients with geographic atrophy from the phase 3 OAKS and DERBY trials with efficacy data from GALE [oral presentation]. Presented at EURETINA Congress; October 5\u20138, 2023; Amsterdam, Netherlands."},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.09.036"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2020.09.024"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-021-00358-w"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2023.2257604"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.08.027"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01583-0"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1159\/000443209"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1177\/24741264231220224"}],"container-title":["Ophthalmic Surgery, Lasers and Imaging Retina"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T12:41:48Z","timestamp":1751978508000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.healio.com\/doi\/10.3928\/23258160-20250217-01"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":20,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.3928\/23258160-20250217-01"],"URL":"https:\/\/doi.org\/10.3928\/23258160-20250217-01","relation":{},"ISSN":["2325-8160","2325-8179"],"issn-type":[{"value":"2325-8160","type":"print"},{"value":"2325-8179","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]}}}